Results of the FAST-TB end-users' survey align with priority research questions on new TB treatment regimens.

Authors

A Bellavia, T A Refera, D R Silva, Y Kherabi, N Singla, Y Permata, R C Teixeira, E Pontali, G Fumagalli, L Lagrutta, M Munoz-Torrico, M Rifat, M B Souleymane, S Villa, C Lienhardt, R Centis, L D'Ambrosio, M C Raviglione, G B Migliori

Published in

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. Volume 30. Issue 10. Pages 427-435. Sep 30, 2026.

Abstract

Rapid adoption and scale-up of new anti-TB regimens requires evidence on efficacy and safety, but also on end-user preferences, implementation barriers, regulatory hurdles, and local conditions. The aim of this study is to describe the extent to which the questions included in a global end-user survey address priority research questions identified through a Delphi process.We used a methodological mapping approach to examine the extent to which questions included in a TB survey and interviews to patients, health care workers, and experts align with seven research questions identified through a recent Delphi process. The content of the survey and interviews was systematically compared and matched against the priority research questions to assess its analytical capacity.The survey contains data relevant to all seven research questions: three with full analytical capacity; three with substantial but incomplete capacity; and one with partial capacity.Mapping and matching exercise indicates that the FAST-TB survey and structured interviews can help identify where additional qualitative, economic, or policy research will be needed to support new regimen development, adoption, and scale-up..

PMID:
42816973
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.